”Small Molecule API Contract Manufacturer Quality Benchmarking (2016)” — quality benchmarking reports now available
Suite of reports provide readers with a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish.
Industry Standard Research (ISR) has announced the addition of three reports to its Contract Manufacturer Quality Benchmarking suite of reports to provide readers a comprehensive assessment of biopharmaceutical CMO service quality across three key areas of outsourced manufacturing: small molecule, biologic and fill finish. As biopharma companies continue to increase their levels of external development and manufacturing, the need for unbiased information to support strategic business decisions remains critical.
These reports provide a Consumer Reports-style analysis where each of the 83 CMOs included in the research was evaluated across 26 service quality attributes, making these reports the most comprehensive assessment of quality in the contract manufacturing space. These 26 attributes were categorized into four 'scorecards': Delivery Factors, Organization Factors, Capabilities, and Staff Characteristics. Respondents were asked to recall their specific experiences working with the manufacturers, and to indicate how well the manufacturer(s) performed with respect to expectations. For buyers of outsourced services, the report includes highly valuable information to help guide CMO selection for small molecule, biologic or fill finish projects from early clinical stages to commercialization.
"There has been a tendency to conflate CMOs' service offerings when it comes to performance evaluations, especially in syndicated research," explained Kate Hammeke, Director of Market Research at Industry Standard Research. "That approach makes it easier to acquire the desired sample size to conduct an analysis, but the insights lack the depth of information both sponsors and contract manufacturers crave. Starting this year, ISR's Contract Manufacturer Quality Benchmarking research has been split into three tracks of data collection, enabling sponsors to evaluate CMOs on specifics related to the type of project for which the CMO was engaged, whether it was for small molecule API, biologic API or fill finish. This depth of information and audience-actual customers who have worked with the CMO in the past 18 months-has previously only been available through custom market research."
CMO performance attributes evaluated by respondents include Reliable on-time delivery, Regulatory History, Quality performance metrics, Scale-up and tech transfer abilities, Scientific knowledge, Right-first-time measurements, and many others.
The reports include data on 83 different contract manufacturing organizations, including: 3M Drug Delivery Systems, AAI/Cambridge Major, AbbVie Contract Manufacturing, Aenova, Aeras CMO, Aesica, AMRI, Albemarle, Almac, Althea, AMPAC Fine Chemicals, Aptuit, Ash Stevens, Avid Bioservices, Baxter BioPharma Solutions, BioReliance, Boehringer Ingelheim, Cambrex, Capsugel, Catalent, Celltrion, Chartwell Pharmaceuticals, CMC Biologics, Cobra Biologics, Cook Pharmica, Corden Pharma, CoreRx, CPL, Cytovance Biologics, Dalton Pharma Services, DPT, Dr. Reddy's CPS, Ei, Emergent Biosolutions, Evonik, Fareva, Flamma, FujiFilm Diosynth Biotechnologies, Glatt Pharmaceutical Services, GSK Contract Manufacturing, Halo Pharma, Helsinn, Hetero, Hospira One2One, Hovione, IDT Biologika, Jubilant HollisterStier, KBI Biopharma, Kemwell, Lonza, Metrics, Neuland, NextPharma, Norwich, Novasep, Paragon, Patheon, PCI Synthesis, Pfizer CentreSource, PharmaCore, Pharmatek, PharmaZell, Pii, Piramal Pharma Solutions, Recipharm, Rentschler, Richter-Helm, Rottendorf Pharma, SAFC, SAI Life Sciences, Samsung BioLogics, Sandoz, Sanofi CEPiA, Siegfried, Symbiosis, Therapure BioPharma, Unither Pharamceuticals, UPM Pharmaceuticals, Vetter, WellSpring, Wockhardt, Xcelience.
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance